Prognostic impact and predictive biomarkers of immune checkpoint inhibitor-induced interstitial lung disease for non-small cell lung cancer

被引：0
|
作者：
Murata, Daiki [1 ]
Azuma, Koichi [1 ]
Matsuo, Norikazu [1 ]
Tokito, Takaaki [1 ]
Hoshino, Tomoaki [1 ]
机构：
[1] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.290
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO55-4
引用
收藏
页码：S1430 / S1430
页数：1
相关论文
共 50 条
  • [1] Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer
    Murata, Daiki
    Azuma, Koichi
    Matama, Goushi
    Zaizen, Yoshiaki
    Matsuo, Norikazu
    Murotani, Kenta
    Tokito, Takaaki
    Hoshino, Tomoaki
    THORACIC CANCER, 2023, 14 (01) : 73 - 80
  • [2] Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer
    Murata, Daiki
    Azuma, Koichi
    Murotani, Kenta
    Matsuo, Norikazu
    Matama, Goushi
    Tokito, Takaaki
    Sasada, Tetsuro
    Hoshino, Tomoaki
    LUNG CANCER, 2023, 184
  • [3] Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer
    Nakanishi, Yu
    Masuda, Takeshi
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Nakashima, Taku
    Miyamoto, Shintaro
    Tsutani, Yasuhiro
    Iwamoto, Hiroshi
    Okada, Morihito
    Hattori, Noboru
    Fujitaka, Kazunori
    Miyata, Yoshihiro
    Hamada, Hironobu
    RESPIRATORY INVESTIGATION, 2019, 57 (05) : 451 - 459
  • [4] Immune Checkpoint Inhibitor-Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases Really Mild and Easily Manageable?
    Ikeda, Satoshi
    Misumi, Toshihiro
    Kato, Terufumi
    Okamoto, Hiroaki
    Ogura, Takashi
    CHEST, 2022, 162 (01) : E65 - E66
  • [5] Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer
    Cho, Uiju
    Im, Soyoung
    Park, Hyung Soon
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2024, 58 (02) : 49 - 58
  • [6] Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer
    Thakur, Manish K.
    Gadgeel, Shirish M.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (05) : 760 - 770
  • [7] Immune Checkpoint Inhibitor-Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases Really Mild and Easily Manageable? Response
    Zhang, Meng
    Cheng, Yuan
    CHEST, 2022, 162 (01) : E66 - E67
  • [8] Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
    Giustini, Nicholas
    Bazhenova, Lyudmila
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 21 - 34
  • [9] Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
    Spakowicz, D.
    Williams, N.
    Bibi, A.
    Hoyd, R.
    Wheeler, C. E.
    Suman, S.
    Amann, J.
    Okimoto, T.
    Grogan, M.
    Vibhakar, P.
    Owen, D.
    Carbone, D. P.
    Presley, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S345 - S346
  • [10] Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer
    Katsurada, Masahiro
    Nagano, Tatsuya
    Tachihara, Motoko
    Kiriu, Tatsunori
    Furukawa, Koichi
    Koyama, Kiyoko
    Otoshi, Takehiro
    Sekiya, Reina
    Hazama, Daisuke
    Tamura, Daisuke
    Nakata, Kyosuke
    Katsurada, Naoko
    Yamamoto, Masatsugu
    Kobayashi, Kazuyuki
    Nishimura, Yoshihiro
    ANTICANCER RESEARCH, 2019, 39 (02) : 815 - 825
12345